The glasgow prognostic score predicts poor survival in cisplatin-based treated patients with metastatic nasopharyngeal carcinoma

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Chen, Cui ^a   Sun, Peng ^b   Dai, Qiang Sheng ^a   Weng, Hui Wen ^a   Li, He Ping ^a   Ye, Sheng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTINUOUS INFUSION; DEMOGRAPHY; FEMALE; FOLLOW UP; GLASGOW PROGNOSTIC SCORE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PREDICTION; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; AREA UNDER THE CURVE; BONE NEOPLASMS; CELL COUNT; INFLAMMATION; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTE; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; SURVIVAL; THROMBOCYTE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BLOOD PLATELETS; BONE NEOPLASMS; CELL COUNT; CISPLATIN; FEMALE; HUMANS; INFLAMMATION; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84911899746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112581     Document Type: Article

References (32)

1. Yu MC, Yuan JM (2002) Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 12: 421-429.
2. Chang ET, Adami HO (2006) The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15: 1765-1777.
3. Chiesa F, De Paoli F (2001) Distant metastases from nasopharyngeal cancer. ORL J Otorhinolaryngol Relat Spec 63: 214-216.
4. Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, et al. (2011) Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128: 79-85.
5. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, et al. (2003) Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol 33: 501-508.
6. Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, et al. (2007) Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 67: 130-137.
7. An X, Wang FH, Ding PR, Deng L, Jiang WQ, et al. (2011) Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117: 3750-3757.
8. McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223-226.
9. Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140: 883-899.
10. Chiang AC, Massague J (2008) Molecular basis of metastasis. N Engl J Med 359: 2814-2823.
11. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, et al. (2013) The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer 13: 52.
12. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, et al. (2012) Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol 29: 3092-3100.
13. Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, et al. (2012) The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinumbased treated patients with metastatic lung cancer. Lung Cancer 77: 383-388.
14. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, et al. (2012) Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol 33: 749-756.
15. McMillan DC (2013) The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev 39: 534-540.
16. An X, Ding PR, Wang FH, Jiang WQ, Li YH (2011) Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 32: 317-324.
17. Maeda K, Shibutani M, Otani H, Nagahara H, Sugano K, et al. (2013) Prognostic value of preoperative inflammation-based prognostic scores in patients with stage IV colorectal cancer who undergo palliative resection of asymptomatic primary tumors. Anticancer Res 33: 5567-5573.
18. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K (2013) Inflammationbased prognostic system predicts survival after surgery for stage IV colorectal cancer. Am J Surg 205: 22-28.
19. Vashist YK, Loos J, Dedow J, Tachezy M, Uzunoglu G, et al. (2011) Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol 18: 1130-1138.
20. Laviano A, Meguid MM, Inui A, Muscaritoli M, Rossi-Fanelli F (2005) Therapy insight: Cancer anorexia-cachexia syndrome-when all you can eat is yourself. Nat Clin Pract Oncol 2: 158-165.
21. Donohoe CL, Ryan AM, Reynolds JV (2011) Cancer cachexia: Mechanisms and clinical implications. Gastroenterol Res Pract 2011: 601434.
22. Fearon KC, Voss AC, Hustead DS (2006) Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83: 1345-1350.
23. Senba M, Zhong XY, Senba MI, Itakura H (1994) EBV and nasopharyngeal carcinoma. Lancet 343: 1104.
24. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, et al. (1997) Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene 14: 2899-2916.
25. Pepys MB, Hirschfield GM (2003) C-reactive protein: A critical update. J Clin Invest 111: 1805-1812.
26. Liaw CC, Wang CH, Huang JS, Kiu MC, Chen JS, et al. (1997) Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. Acta Oncol 36: 159-164.
27. Fuchs CS, Ogino S (2013) Aspirin therapy for colorectal cancer with PIK3CA mutation: Simply complex!. J Clin Oncol 31: 4358-4361.
28. Gridelli C, Gallo C, Ceribelli A, Gebbia V, Gamucci T, et al. (2007) Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: The GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol 8: 500-512.
29. Szumilo J, Burdan F, Szumilo M, Lewkowicz D, Kedzierawska-Kurylcio A (2009) Cyclooxygenase inhibitors in chemoprevention and treatment of esophageal squamous cell carcinoma. Pol Merkur Lekarski 27: 408-412.
30. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, et al. (2012) Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 17: 216-222.
31. Feng JF, Huang Y, Chen QX (2014) Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol 12: 58.
32. He JR, Shen GP, Ren ZF, Qin H, Cui C, et al. (2012) Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck 34: 1769-1776.